Biocartis Group NV (LTS:0R72) EPS (Diluted): €-0.92 (TTM As of Jun. 2023)


LTS:0R72 Biocartis Group NV LTS:0R72
14 GF Score
Price €0.30
View Full Analysis

What is Biocartis Group NV EPS (Diluted)?

Biocartis Group NV LTS:0R72 14 EPS (Diluted) is €-0.92 as of Jun. 2023. GuruFocus rates LTS:0R72 with a GF Score™ of 14/100.

Biocartis Group NV's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was €-0.34. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.92.

Biocartis Group NV's EPS (Basic) for the six months ended in Jun. 2023 was €-0.34. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.92.

Biocartis Group NV's EPS without NRI for the six months ended in Jun. 2023 was €-0.34. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.92.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Biocartis Group NV  (LTS:0R72) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biocartis Group NV EPS (Diluted) Related Terms


Biocartis Group NV EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV EPS (Diluted) Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.80 -0.97 -0.95 -1.24 -1.08

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.69 -0.50 -0.58 -0.34

LTS:0R72 vs TMO, DHR, IDXX: EPS (Diluted) Comparison

For the Diagnostics & Research subindustry, Biocartis Group NV's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocartis Group NV PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's PE Ratio falls into.


LTS:0R72
14GF Score
Biocartis Group NV LTS:0R72
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Biocartis Group NV's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-65.381-0)/60.546
=-1.08

Biocartis Group NV's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-31.254-0)/93.231
=-0.34

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of €-0.92 mean?
Biocartis Group NV (LTS:0R72) has a EPS (Diluted) of €-0.92 as of Jun. 2023. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Biocartis Group NV and its competitors.
Is Biocartis Group NV's EPS (Diluted) too high?
Biocartis Group NV's current EPS (Diluted) is €-0.92. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's EPS (Diluted) compare to TMO and DHR?
Biocartis Group NV's EPS (Diluted) of €-0.92 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Medical Diagnostics & Research company?
A good EPS (Diluted) depends on the Medical Diagnostics & Research industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Biocartis Group NV and its competitors. Biocartis Group NV's current EPS (Diluted) is €-0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current EPS (Diluted) of €-0.92. The current EPS (Diluted) is €-0.92. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current EPS (Diluted) is €-0.92 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for LTS:0R72

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price